109 related articles for article (PubMed ID: 8784653)
1. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.
Stein MB; Chartier MJ; Hazen AL; Kroft CD; Chale RA; Coté D; Walker JR
J Clin Psychopharmacol; 1996 Jun; 16(3):218-22. PubMed ID: 8784653
[TBL] [Abstract][Full Text] [Related]
2. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
Stein MB; Liebowitz MR; Lydiard RB; Pitts CD; Bushnell W; Gergel I
JAMA; 1998 Aug; 280(8):708-13. PubMed ID: 9728642
[TBL] [Abstract][Full Text] [Related]
3. Double-blind placebo-controlled pilot study of paroxetine for specific phobia.
Benjamin J; Ben-Zion IZ; Karbofsky E; Dannon P
Psychopharmacology (Berl); 2000 Apr; 149(2):194-6. PubMed ID: 10805616
[TBL] [Abstract][Full Text] [Related]
4. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa.
Stein DJ; Berk M; Els C; Emsley RA; Gittelson L; Wilson D; Oakes R; Hunter B
S Afr Med J; 1999 Apr; 89(4):402-6. PubMed ID: 10341825
[TBL] [Abstract][Full Text] [Related]
5. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.
Stein MB; Sareen J; Hami S; Chao J
Am J Psychiatry; 2001 Oct; 158(10):1725-7. PubMed ID: 11579011
[TBL] [Abstract][Full Text] [Related]
6. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
Baldwin D; Bobes J; Stein DJ; Scharwächter I; Faure M
Br J Psychiatry; 1999 Aug; 175():120-6. PubMed ID: 10627793
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
8. The Kutcher Generalized Social Anxiety Disorder Scale for Adolescents: assessment of its evaluative properties over the course of a 16-week pediatric psychopharmacotherapy trial.
Brooks SJ; Kutcher S
J Child Adolesc Psychopharmacol; 2004; 14(2):273-86. PubMed ID: 15319024
[TBL] [Abstract][Full Text] [Related]
9. Paroxetine in social phobia.
Mancini C; Ameringen MV
J Clin Psychiatry; 1996 Nov; 57(11):519-22. PubMed ID: 8968300
[TBL] [Abstract][Full Text] [Related]
10. Bupropion-SR in treatment of social phobia.
Emmanuel NP; Brawman-Mintzer O; Morton WA; Book SW; Johnson MR; Lorberbaum JP; Ballenger JC; Lydiard RB
Depress Anxiety; 2000; 12(2):111-3. PubMed ID: 11091936
[TBL] [Abstract][Full Text] [Related]
11. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial.
Van Ameringen M; Mancini C; Oakman J; Walker J; Kjernisted K; Chokka P; Johnston D; Bennett M; Patterson B
J Clin Psychiatry; 2007 Feb; 68(2):288-95. PubMed ID: 17335328
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
Seedat S; Stein MB
J Clin Psychiatry; 2004 Feb; 65(2):244-8. PubMed ID: 15003080
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine in social anxiety disorder: a randomized placebo-controlled study.
Allgulander C
Acta Psychiatr Scand; 1999 Sep; 100(3):193-8. PubMed ID: 10493085
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.
Stein DJ; Versiani M; Hair T; Kumar R
Arch Gen Psychiatry; 2002 Dec; 59(12):1111-8. PubMed ID: 12470127
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
16. Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: initial validation of an imaging protocol for drug discovery.
Giménez M; Ortiz H; Soriano-Mas C; López-Solà M; Farré M; Deus J; Martín-Santos R; Fernandes S; Fina P; Bani M; Zancan S; Pujol J; Merlo-Pich E
Eur Neuropsychopharmacol; 2014 Jan; 24(1):105-16. PubMed ID: 24332890
[TBL] [Abstract][Full Text] [Related]
17. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment.
Walker JR; Van Ameringen MA; Swinson R; Bowen RC; Chokka PR; Goldner E; Johnston DC; Lavallie YJ; Nandy S; Pecknold JC; Hadrava V; Lane RM
J Clin Psychopharmacol; 2000 Dec; 20(6):636-44. PubMed ID: 11106135
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial.
Connor KM; Cook JL; Davidson JR
J Clin Psychiatry; 2006 Jan; 67(1):30-6. PubMed ID: 16426085
[TBL] [Abstract][Full Text] [Related]
19. Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression.
Le Noury J; Nardo JM; Healy D; Jureidini J; Raven M; Tufanaru C; Abi-Jaoude E
Int J Risk Saf Med; 2016 Sep; 28(3):143-61. PubMed ID: 27662279
[TBL] [Abstract][Full Text] [Related]
20. Paroxetine treatment of mood and anxiety disorders in children and adolescents.
Wagner KD
Psychopharmacol Bull; 2003; 37 Suppl 1():167-75. PubMed ID: 14566209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
